The DOI matches its Crossref record; 276 of the 276 references it cites were found in a registry or an index.
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Open accessAbstract
Rheumatoid arthritis (RA) is an autoimmune disease that involves multiple joints bilaterally. It is characterized by an inflammation of the tendon (tenosynovitis) resulting in both cartilage destruction and bone erosion. While until the 1990s RA frequently resulted in disability, inability to work, and increased mortality, newer treatment options have made RA a manageable disease. Here, great progress has been made in the development of disease-modifying anti-rheumatic drugs (DMARDs) which target inflammation and thereby prevent further joint damage. The available DMARDs are subdivided into (1) conventional synthetic DMARDs (methotrexate, hydrochloroquine, and sulfadiazine), (2) targeted synthetic DMARDs (pan-JAK- and JAK1/2-inhibitors), and (3) biologic DMARDs (tumor necrosis factor (TNF)-α inhibitors, TNF-receptor (R) inhibitors, IL-6 inhibitors, IL-6R inhibitors, B cell depleting antibodies, and inhibitors of co-stimulatory molecules). While DMARDs have repeatedly demonstrated the potential to greatly improve disease symptoms and prevent disease progression in RA patients, they are associated with considerable side-effects and high financial costs. This review summarizes our current understanding of the underlying pathomechanism, diagnosis of RA, as well as the mode of action, clinical benefits, and side-effects of the currently available DMARDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–276 of 276
Expression and function of the NALP3 inflammasome in rheumatoid synovium
Kolly, L., Busso, N., Palmer, G., Talabot‐Ayer, D., Chobaz, V., & So, A. K.-L. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03174.x · Cited by 112
Emery, P. E., Bingham, C. O., Burmester, G. R., Bykerk, V. P., Furst, D. E., Xavier Mariette, A., van der Heijde, D. M. F. M., van Vollenhoven, R., Arendt, C. H., Mountian, I., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209057 · Cited by 109
Olalekan, S. A., Cao, Y., Hamel, K. M., & Finnegan, A. (2015) · European Journal of Immunology · doi:10.1002/eji.201445036 · Cited by 107
Williams, T. N., Zhang, C. X., Game, B. A., He, L., & Huang, Y. Q. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000104014.24367.16 · Cited by 106
Role of C-reactive protein in osteoclastogenesis in rheumatoid arthritis
Kim, K., Kim, B., Moon, H., Lee, S., & Kim, H. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0563-z · Cited by 106
The use of methotrexate in rheumatoid arthritis
Borchers, A. T., Keen, C. L., Cheema, G. S., & Gershwin, M. E. (2004) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2003.12.003 · Cited by 105
Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells
Lorenzetti, R., Janowska, I., Smulski, C. R., Frede, N., Henneberger, N., Walter, L. I., Schleyer, M.-T., Hüppe, J. M., Staniek, J., Salzer, U., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.04.016 · Cited by 105
Tan, E. M., & Smolen, J. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160792 · Cited by 103
Antimalarials for treating rheumatoid arthritis
Suarez-Almazor, M. E., Belseck, E. M., Shea, B., Homik, J., Wells, G. A., & Tugwell, P. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000959 · Cited by 102
Coutant, F., & Miossec, P. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000664 · Cited by 102
Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
Raimondo, M., Biggioggero, M., Crotti, C., Becciolini, A., & Favalli, E. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s100302 · Cited by 100
Sun, Y., Wang, D., Salvadore, G., Hsu, B., Curran, M., Casper, C., Vermeulen, J., Kent, J. M., Singh, J., Drevets, W. C., et al. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.06.014 · Cited by 100
Epigenetics in the pathogenesis of RA
Ospelt, C., Gay, S., & Klein, K. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0621-5 · Cited by 99
Takase‐Minegishi, K., Horita, N., Kobayashi, K., Yoshimi, R., Kirino, Y., Ohno, S., Kaneko, T., Nakajima, H., Wakefield, R. J., & Emery, P. (2017) · Rheumatology · doi:10.1093/rheumatology/kex036 · Cited by 98
Emery, P., Rondon, J., Parrino, J., Lin, Y., Pena-Rossi, C., van Hoogstraten, H., Graham, N. M. H., Liu, N., Paccaly, A., Wu, R., et al. (2019) · Rheumatology · doi:10.1093/rheumatology/key361 · Cited by 95
Self-citationPierer, M., Wagner, U. G., Rossol, M., & Ibrahim, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023539 · Cited by 94
The potential aggressiveness of synovial tissue in rheumatoid arthritis
Fassbender, H. G., & Simmling‐Annefeld, M. (1983) · The Journal of Pathology · doi:10.1002/path.1711390314 · Cited by 94
Ryu, S., Lee, J. H., & Kim, S. I. (2005) · Clinical Rheumatology · doi:10.1007/s10067-005-1081-1 · Cited by 92
for the NEXUS Study Group, Taylor, P. C., Saurigny, D., Vencovský, J., Takeuchi, T., Nakamura, T., Matsievskaia, G., Hunt, B., Wagner, T., & Souberbielle, B. E. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1879-x · Cited by 89
Nabata, A., Kuroki, M., Ueba, H., Hashimoto, S., Umemoto, T., Wada, H., Yasu, T., Saito, M., Momomura, S., & Kawakami, M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.03.003 · Cited by 88
Yoshimi, R., Hama, M., Takase, K., Ihata, A., Kishimoto, D., 寺内佳余, Watanabe, R., Uehara, T., Samukawa, S., Ueda, A., et al. (2012) · Modern Rheumatology · doi:10.1007/s10165-012-0690-1 · Cited by 85
Perforin and granzyme A expression identifying cytolytic lymphocytes in rheumatoid arthritis.
Griffiths, G. M., Alpert, S. D., Lambert, E., McGuire, J. L., & Weissman, I. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.2.549 · Cited by 84
Global Molecular Effects of Tocilizumab Therapy in Rheumatoid Arthritis Synovium
Ducreux, J., Durez, P., Galant, C., Toukap, A. N., den Eynde, B. J. V., Houssiau, F. A., & Lauwerys, B. R. (2013) · Arthritis & Rheumatology · doi:10.1002/art.38202 · Cited by 84
Etanercept in rheumatoid arthritis
Alldred, A. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.7.1137 · Cited by 83
Thanapati, S., Ganu, M. A., Giri, P. S., Kulkarni, S. P., Sharma, M., Babar, P., Ganu, A., & Tripathy, A. S. (2017) · Human Immunology · doi:10.1016/j.humimm.2017.02.006 · Cited by 82
Komaki, F., Komaki, Y., Micić, D., Ido, A., & Sakuraba, A. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.11.004 · Cited by 81
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
Mihara, M., Ohsugi, Y., & Kishimoto (2011) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s17118 · Cited by 80
Finckh, A., Simard, J. F., Duryea, J., Liang, M. H., Huang, J., Daneel, S., Forster, A., Gabay, C., & Guerne, P. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21491 · Cited by 78
Monnet, E., Choy, E., McInnes, I. B., Kobakhidze, T., de Graaf, K., Jacqmin, P., Lapeyre, G., & de Min, C. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216487 · Cited by 77
The detection and initial characterization of colony-stimulating factors in synovial fluid.
Williamson, D. J., Begley, C. G., Vadas, M. A., & Metcalf, D. (1988) · PubMed Central · Cited by 76
Fasth, A. E. R., Cao, D., Van Vollenhoven, R., Trollmo, C., & Malmström, V. (2004) · Scandinavian Journal of Immunology · doi:10.1111/j.0300-9475.2004.01464.x · Cited by 73
Scarsi, M., Paolini, L., Ricotta, D., Pedrini, A., Piantoni, S., Caimi, L., Tincani, A., & Airó, P. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130905 · Cited by 73
Brody, M., Böhm, I., & Bauer, R. (1993) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1993.31.10.667 · Cited by 73
Arleevskaya, M. I., Kravtsova, O. A., Lemerle, J., Renaudineau, Y., & Цибулькин, А. П. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01296 · Cited by 73
Elevated circulating Th17 and follicular helper CD4+ T cells in patients with rheumatoid arthritis
Zhang, Y., Yu, L., Lv, T., Yin, Z., & Wang, X. (2015) · Apmis · doi:10.1111/apm.12399 · Cited by 69
Steiner, G. E. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/bf02686079 · Cited by 68
C-reactive protein induces M-CSF release and macrophage proliferation
Devaraj, S., Yun, J., Duncan‐Staley, C., & Jialal, I. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0808458 · Cited by 66
Tournadre, A., Lenief, V., Eljaafari, A., & Miossec, P. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33350 · Cited by 65
Khatami, G., Mir-Nasseri, M., Seyghali, F., Allah-Verdi, B., & Yourdkhani, F. (2010) · PubMed Central · Cited by 65
McKenna, M. R., Stobaugh, D. J., & Deepak, P. (2014) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.233.mrmk · Cited by 65
Özen, G., Pedro, S., Schumacher, R., Simon, T. A., & Michaud, K. D. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1921-z · Cited by 65
Kim, S. C., Pawar, A. M., Desai, R. J., Solomon, D. H., Gale, S. L., Bao, M., Sarsour, K., & Schneeweiß, S. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.03.002 · Cited by 64
van Bezooijen, R. L., Papapoulos, S. E., & Löwik, C. W. G. M. (2001) · Bone · doi:10.1016/s8756-3282(00)00457-9 · Cited by 62
Curtis, J. R., Xie, F., Chen, L., Muntner, P., Grijalva, C. G., Spettell, C. M., Fernandes, J. F., Mcmahan, R. M., Baddley, J. W., Saag, K. G., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21805 · Cited by 62
Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?
Avcı, A. B., Feist, E., & Burmester, G. R. (2018) · BioDrugs · doi:10.1007/s40259-018-0320-3 · Cited by 62
Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis
Ogata, A., Hirano, T., Hishitani, Y., & Tanaka, T. (2012) · Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders · doi:10.4137/cmamd.s7371 · Cited by 61
Chen, J., Li, J., Gao, H., Wang, C., Luo, J., Lv, Z., & Li, X. (2012) · BioMed Research International · doi:10.1155/2012/535361 · Cited by 60
Yamanishi, Y., Boyle, D. L., Green, D. R., Keystone, E. C., Connor, A. M., Zollman, S., & Firestein, G. S. (2004) · Arthritis Research & Therapy · doi:10.1186/ar1448 · Cited by 56
Bözec, A., Luo, Y., Engdahl, C., Figueiredo, C. P., Bang, H., & Schett, G. A. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1527-x · Cited by 55
Pollastro, S., Klarenbeek, P. L., Doorenspleet, M. E., van Schaik, B. D. C., Esveldt, R. E., Thurlings, R. M., Boumans, M. J. H., Gerlag, D. M., Tak, P. P., Vos, K., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214898 · Cited by 55
Zhang, Q., Li, Q., Zhu, J., Guo, H., Zhai, Q., Li, B., Jin, Y. J., He, X., & Jin, F. (2019) · PeerJ · doi:10.7717/peerj.7023 · Cited by 54
Bone and cartilage regeneration with the use of umbilical cord mesenchymal stem cells
Klontzas, M. E., Kenanidis, E. I., Heliotis, M., Tsiridis, E. E., & Mantalaris, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1068755 · Cited by 53
Secukinumab for rheumatology: development and its potential place in therapy
Koenders, M., & van den Berg, W. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s105263 · Cited by 51
Tiwana, H., Wilson, C., Alvarez, A., Abuknesha, R. A., Bansal, S. S., & Ebringer, A. (1999) · Infection and Immunity · doi:10.1128/iai.67.6.2769-2775.1999 · Cited by 50
Plater-Zyberk, C., Joosten, L. A. B., Helsen, M. M., Hepp, J., Baeuerle, P. A., & van den Berg, W. B. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.057182 · Cited by 49
Wilson, C., Tiwana, H., & Ebringer, A. (2000) · Microbes and Infection · doi:10.1016/s1286-4579(00)01303-4 · Cited by 48
Genetics of rheumatoid arthritis: GWAS and beyond
Orozco, G., Duffus, K., & Eyre, S. (2011) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s14725 · Cited by 48
An Evaluation of the Effect of Dental Foci of Infection on Health
Easlick, K. A. (1951) · The Journal of the American Dental Association · doi:10.14219/jada.archive.1951.0112 · Cited by 47
Are Janus kinase inhibitors superior over classic biologic agents in RA patients?
Kotyla, P. J. (2018) · BioMed Research International · doi:10.1155/2018/7492904 · Cited by 47
Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials.
Weinblatt, M. E., Reda, D. J., Henderson, W., Giobbie‐Hurder, A., Williams, D., Diani, A., & Docsa, S. (1999) · PubMed · Cited by 46
Evaluation of anti-IL-6 monoclonal antibody therapy using murine type II collagen-induced arthritis
Liang, B., Song, Z., Wu, B., Gardner, D. B., Shealy, D. J., Song, X.-Y., & Wooley, P. H. (2009) · Journal of Inflammation · doi:10.1186/1476-9255-6-10 · Cited by 44
Rafique, A., Martin, J., Blome, M., Huang, T. T., Ouyang, A., & Papadopoulos, N. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-eular.2360 · Cited by 43
Drug use and toxicity in psoriatic disease: focus on methotrexate.
Taylor, W. J., Korendowych, E., Nash, P. T., Helliwell, P., Choy, E., Krueger, G. G., Soriano, E. R., McHugh, N. J., & Rosen, C. F. (2008) · PubMed · Cited by 42
EOMES‐positive CD4+ T cells are increased in PTPN22 (1858T) risk allele carriers
Chemin, K., Ramsköld, D., Díaz-Gallo, L.-M., Herrath, J., Houtman, M., Tandre, K., Rönnblom, L., Catrina, A. I., & Malmström, V. (2018) · European Journal of Immunology · doi:10.1002/eji.201747296 · Cited by 42
Graudal, N. A., Hubeck‐Graudal, T., Tarp, S., Christensen, R., & Jűrgens, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106408 · Cited by 37
Fleischmann, R., Weinblatt, M. E., Schiff, M. H., Khanna, D., Maldonado, M. A., Nadkarni, A., & Fürst, D. E. (2015) · Arthritis Care & Research · doi:10.1002/acr.22763 · Cited by 35
Intravenous Tocilizumab: A Review of Its Use in Adults with Rheumatoid Arthritis
Dhillon, S. (2013) · BioDrugs · doi:10.1007/s40259-013-0076-8 · Cited by 34
Karonitsch, T., von Dalwigk, K., Steiner, C.-W., Blüml, S., Steiner, G. E., Kiener, H. P., Smolen, J. S., & Aringer, M. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33347 · Cited by 33
Genovese, M. C., Pacheco‐Tena, C., Covarrubias, A., León, G., Mysler, E., Keiserman, M. W., Valente, R., Nash, P. T., Campos, J. A. S., Box, J., et al. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130112 · Cited by 33
Chloroquine-induced bull’s eye maculopathy in rheumatoid arthritis: related to disease duration?
Shinjo, S. K., Júnior, O. D. O. M., Tizziani, V. A. P., Morita, C., Kochen, J. A. L., Takahashi, W. Y., & Laurindo, I. M. M. (2007) · Clinical Rheumatology · doi:10.1007/s10067-006-0478-9 · Cited by 32
Coutant, F. (2019) · Joint Bone Spine · doi:10.1016/j.jbspin.2019.01.005 · Cited by 27
Burmester, G., Panaccione, R., Gordon, K. B., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-eular.3077 · Cited by 14
Sulfasalazine-Related Hypersensitivity Reactions in Patients With Rheumatic Diseases
Çildağ, S., & Şentürk, T. (2017) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000490 · Cited by 14
Interferon‐γ facilitated adjuvant‐induced arthritis at early stage
Ma, H., Xu, M., Song, Y., Zhang, T., Yin, H., & Yin, S. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12757 · Cited by 9
Peichl, P., Alten, R., Galeazzi, M., et al. (2019) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-019-00710-8 · Cited by 8
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Cited by
Management of Rheumatoid Arthritis: An Overview
Radu, A.-F., & Bungau, S. G. (2021) · Cells · doi:10.3390/cells10112857 · Cited by 1,089
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
Chronic tissue inflammation and metabolic disease
Lee, Y. S., & Olefsky, J. (2021) · Genes & Development · doi:10.1101/gad.346312.120 · Cited by 335
Traditional herbal medicine: Therapeutic potential in rheumatoid arthritis
Wang, Y., Chen, S., Du, K., Liang, C., Wang, S., Owusu Boadi, E., Li, J., Pang, X., He, J., & Chang, Y.-X. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114368 · Cited by 264
Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment
Wu, D., Luo, Y., Li, T., Zhao, X., Lv, T., Fang, G., Ou, P., Li, H., Luo, X., Huang, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1051082 · Cited by 263
Metadata
- Authors
- Lin, Y.-J., Anzaghe, M., & Schülke, S.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-04-03
- Volume
- 9
- Issue
- 4
- Pages
- 880
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3014146563
- Cited by
- 932
- References
- 276
- FWCI
- 69.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.